RecruitingNot ApplicableNCT06835959
Moms@Home: A Storytelling-based Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy
Development of a Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy (Moms@Home)
Sponsor
University of Massachusetts, Worcester
Enrollment
100 participants
Start Date
May 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This pilot study will examine the effects of a digital health approach, Moms@Home, on home blood pressure monitoring in a diverse population of pregnant women with hypertension.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years
Inclusion Criteria7
- Age 18-50
- English or Spanish speaking
- A diagnosis of gestational (20-26 weeks gestational age) or chronic hypertension (8-26 weeks gestational age)
- Singleton or multiple gestation pregnancy,
- A patient of the University of Massachusetts Memorial Health Obstetrics/Maternal and Fetal Medicine clinics in Worcester, Massachusetts
- Willing to share home blood pressure monitoring data
- Comfortable with the use of smartphones and mobile apps
Exclusion Criteria8
- Severe hypertension (Systolic blood pressure ≥160 mmHg or Diastolic blood pressure ≥100 mmHg)
- Current diagnosis of preeclampsia
- Active substance use
- Serious physical illness (e.g., unable to interact with a smart device)
- Enrolled in another home blood pressure monitoring program
- Excluded from study participation by their provider
- Inability to provide informed consent
- Prisoners/institutionalized individuals
Interventions
BEHAVIORALMoms@Home
Participants will use a storytelling mobile health app for daily home-based blood pressure monitoring and symptom/medication adherence tracking.
BEHAVIORALEnhanced Standard of Care
Participants will use a paper journal daily to track home-based blood pressure values
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06835959
Related Trials
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
NCT067851161 location
Treatment With Aspirin After Preeclampsia: TAP Trial
NCT062816651 location
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
NCT073492771 location
LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
NCT073616791 location
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT0646820216 locations